ID   HCC1806r5-F1500
AC   CVCL_D6VJ
SY   HCC1806 r5-Fluorouracil1500
RX   PubMed=40300663;
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Part of: Resistant Cancer Cell Line (RCCL) collection.
CC   Population: African American.
CC   Selected for resistance to: ChEBI; CHEBI_46345; 5-fluorouracil (5-FU).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Thr256Lysfs*90 (c.766_767insAA); Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Breast; UBERON=UBERON_0000310.
DI   NCIt; C40359; Breast acantholytic squamous cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1258 ! HCC1806
SX   Female
AG   60Y
CA   Cancer cell line
DT   Created: 10-09-24; Last updated: 14-08-25; Version: 4
//
RX   PubMed=40300663; DOI=10.1016/j.canlet.2025.217754;
RA   Grimsley, Helen E.
RA   Antczak, Magdalena
RA   Reddin, Ian G.
RA   Weiler, Nicole
RA   McLaughlin, Katie-May
RA   Rothweiler, Florian
RA   Haas, Johannes
RA   Nist, Andrea
RA   Mernberger, Marco
RA   Stiewe, Thorsten
RA   Fenton, Tim R.
RA   Speidel, Daniel
RA   Harper-Wynne, Catherine
RA   Cox, Karina
RA   Heckl, Dirk
RA   Cinatl, Jindrich Jr.
RA   Wass, Mark N.
RA   Garrett, Michelle D.
RA   Michaelis, Martin
RT   "Using a novel panel of drug-resistant triple-negative breast cancer
RT   cell lines to identify candidate therapeutic targets and biomarkers.";
RL   Cancer Lett. 624:217754.1-217754.14(2025).
//